Magnolia

The Cytonet group is active in the field of medical biotechnology Mannheim, March 24, 2010. The Cytonet group is active in the field of medical biotechnology and new customer of the Mannheim agency magnolia. The agency designed a new claim for Cytonet first, developed a brochure and a presentation. Cytonet in the cell therapy is already the largest companies of in Germany. The company develops, produces and markets new, cell-based medical products.

Cytonet partners are internationally leading university hospitals. Whose research is transmitted in their own procedural approaches and promising technologies to develop pioneering products. The Mannheim full service agency could convince through their work and as a new customer win Cytonet. In addition to daily work, the Agency was charged with the conception of a new claims which makes clear the positioning on the market and the positioning within the industry. As more projects get Development of a brochure as well as a fair map. Cytonet to increasingly as a first mover\”in the medically focused biotechnology cell research are perceived. The Cytonet is group as spin-off of the cell therapy Division of the Roche Diagnostics company founded and established himself as Germany’s leader in cell therapy with headquarters in Weinheim. Production sites are located in Heidelberg, Hanover and Durham (NC, United States).

Dietmar Hopp, co-founder of SAP, invested in Cytonet. Today are Dietmar Hopp and his family’s majority shareholder. About Cytonet: The Cytonet group is active in the field of medical biotechnology. Cytonet in the cell therapy is already the largest companies of in Germany. The company develops, produces and markets new, cell-based medical products. Cytonet partners are internationally leading university hospitals. Their research will be transmitted in their own procedural approaches and promising technologies to this groundbreaking Products to develop. The company is focused on developments that offer new therapies for life-threatening liver disease. Currently, a clinical study investigates the effect of Leberzelltherapie with congenital metabolic disorders of the urea cycle in newborns.